Cite
MLA Citation
Gil Awada et al.. “Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).” Journal for immunotherapy of cancer, vol. 8, no. 2, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100127573410.0x00002d